Percutaneous electrical stimulation is effective in reducing chronic knee pain and improving functionality in affected patients.

Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

They enrolled patients with knee osteoarthritis from 2 Phase 2 and 2 Phase 3 trials with Kellgren-Lawrence (KL) Grades 2–3 ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

The following is a summary of “Pain-related impairment in daily activities after lung cancer surgery: A 1-year prospective cohort study” published in the November 2024 issue of Pain by Danielsen et al ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Phase III MANEUVER trial ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Patient-reported symptom information allows radiologists to achieve near-perfect diagnostic agreement with clinical exp ...

including stiffness by Numeric Rating Scale (NRS; -3.00 mean change from baseline versus -0.57 for placebo, p<0.0001) and ...

A 57-year-old man suffering from debilitating pain, numbness, and difficulty walking found relief through immunotherapy, ...